CY1113622T1 - Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης - Google Patents

Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης

Info

Publication number
CY1113622T1
CY1113622T1 CY20121101168T CY121101168T CY1113622T1 CY 1113622 T1 CY1113622 T1 CY 1113622T1 CY 20121101168 T CY20121101168 T CY 20121101168T CY 121101168 T CY121101168 T CY 121101168T CY 1113622 T1 CY1113622 T1 CY 1113622T1
Authority
CY
Cyprus
Prior art keywords
fluorophenoxymethyl
piperidine
phenyl
compound
crystalline form
Prior art date
Application number
CY20121101168T
Other languages
English (en)
Inventor
Lori Jean Patterson
Robert Chao
Miroslav Rapta
Original Assignee
Theravance, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance, Inc. filed Critical Theravance, Inc.
Publication of CY1113622T1 publication Critical patent/CY1113622T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Η εφεύρεση παρέχει ένα κρυσταλλικό υδροχλωρικό άλας της 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδίνης. Η εφεύρεση αυτή παρέχει επίσης φαρμακευτικές συνθέσεις οι οποίες περιέχουν το κρυσταλλικό άλας, διαδικασίες και ενδιάμεσες ενώσεις για την παρασκευή του κρυσταλλικού άλατος και μεθόδους για τη χρήση του κρυσταλλικού άλατος για τη θεραπευτική αντιμετώπιση νόσων.
CY20121101168T 2008-11-14 2012-11-29 Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης CY1113622T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14
EP09752988A EP2358676B1 (en) 2008-11-14 2009-11-13 Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

Publications (1)

Publication Number Publication Date
CY1113622T1 true CY1113622T1 (el) 2016-06-22

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20121101168T CY1113622T1 (el) 2008-11-14 2012-11-29 Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης
CY20121101189T CY1113623T1 (el) 2008-11-14 2012-12-07 Ενωσεις 4-[2-(2-φθοροφαινοξυμεθυλ)φαινυλ]πιπεριδινης
CY20131100256T CY1113855T1 (el) 2008-11-14 2013-03-26 Διεργασια για την παρασκευη ενωσεων 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20121101189T CY1113623T1 (el) 2008-11-14 2012-12-07 Ενωσεις 4-[2-(2-φθοροφαινοξυμεθυλ)φαινυλ]πιπεριδινης
CY20131100256T CY1113855T1 (el) 2008-11-14 2013-03-26 Διεργασια για την παρασκευη ενωσεων 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης

Country Status (29)

Country Link
US (23) US8247433B2 (el)
EP (3) EP2358676B1 (el)
JP (6) JP5598798B2 (el)
KR (3) KR101685186B1 (el)
CN (3) CN102209712B (el)
AR (3) AR074128A1 (el)
AU (3) AU2009313948B2 (el)
BR (3) BRPI0921595B8 (el)
CA (3) CA2742114C (el)
CL (2) CL2011001088A1 (el)
CO (2) CO6361988A2 (el)
CY (3) CY1113622T1 (el)
DK (3) DK2358674T3 (el)
ES (3) ES2401224T3 (el)
HK (3) HK1160449A1 (el)
HR (3) HRP20120897T1 (el)
IL (2) IL212230A (el)
MX (3) MX2011005088A (el)
MY (2) MY151211A (el)
NZ (2) NZ592413A (el)
PL (3) PL2358676T3 (el)
PT (3) PT2358675E (el)
RU (2) RU2503662C2 (el)
SG (1) SG171311A1 (el)
SI (3) SI2358676T1 (el)
SM (3) SMT201200063B (el)
TW (3) TWI461407B (el)
WO (3) WO2010056938A1 (el)
ZA (1) ZA201103495B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056938A1 (en) 2008-11-14 2010-05-20 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) * 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
US20110263631A1 (en) * 2010-04-22 2011-10-27 Martin William J Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
US9115133B2 (en) 2011-03-22 2015-08-25 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
MX370970B (es) * 2016-08-30 2020-01-10 Theravance Biopharma R&D Ip Llc Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica.
ES2960492T3 (es) * 2018-06-01 2024-03-05 Theravance Biopharma R&D Ip Llc Procedimiento para la preparación de ácido 2-(1-(terc-butoxicarbonil)piperidín-4-il)benzoico
TW202345817A (zh) 2022-03-28 2023-12-01 美商施萬生物製藥研發 Ip有限責任公司 治療患有多系統萎縮之個體的方法
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
AU4637899A (en) * 1998-07-10 2000-02-01 Astrazeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CZ20013424A3 (cs) * 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
US6630504B2 (en) * 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2004017977A2 (en) * 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
UA81469C2 (en) * 2003-04-04 2008-01-10 Lundbeck & Co As H 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
JP2006522027A (ja) * 2003-04-04 2006-09-28 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルオキシフェニル）−ピペリジンまたは−１，２，３，６−テトラヒドロピリジン誘導体
WO2004110995A1 (en) * 2003-06-17 2004-12-23 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
US20070105870A1 (en) * 2004-01-13 2007-05-10 Pfizer Inc. Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
WO2008023258A1 (en) 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
WO2008039418A2 (en) * 2006-09-27 2008-04-03 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
WO2010008739A2 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
WO2010056938A1 (en) * 2008-11-14 2010-05-20 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
MX370970B (es) * 2016-08-30 2020-01-10 Theravance Biopharma R&D Ip Llc Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica.

Also Published As

Publication number Publication date
AR074128A1 (es) 2010-12-22
RU2515612C2 (ru) 2014-05-20
US10576073B2 (en) 2020-03-03
KR20110082197A (ko) 2011-07-18
JP5529150B2 (ja) 2014-06-25
SMT201200065B (it) 2013-03-08
PT2358676E (pt) 2012-12-06
PT2358675E (pt) 2012-12-12
US20240316024A1 (en) 2024-09-26
US20160184288A1 (en) 2016-06-30
MY151211A (en) 2014-04-30
NZ592413A (en) 2013-02-22
US8802857B2 (en) 2014-08-12
US20140045892A1 (en) 2014-02-13
JP5506813B2 (ja) 2014-05-28
ES2401224T3 (es) 2013-04-17
US8604058B2 (en) 2013-12-10
US10722504B2 (en) 2020-07-28
CA2742105C (en) 2016-09-13
HK1160448A1 (en) 2012-08-17
US20200000792A1 (en) 2020-01-02
TWI441810B (zh) 2014-06-21
HRP20120897T1 (hr) 2012-12-31
ES2397247T3 (es) 2013-03-05
IL212230A0 (en) 2011-06-30
US10206913B2 (en) 2019-02-19
BRPI0921596A2 (pt) 2018-03-20
AU2009313949B2 (en) 2015-03-19
US11596624B2 (en) 2023-03-07
CN102209712A (zh) 2011-10-05
CA2742114C (en) 2016-09-13
CL2011001088A1 (es) 2011-10-14
US20130030185A1 (en) 2013-01-31
MX2011005088A (es) 2011-06-01
EP2358675B1 (en) 2012-10-03
US20120277438A1 (en) 2012-11-01
BRPI0921593B8 (pt) 2021-05-25
SMT201200063B (it) 2013-01-14
US20200316048A1 (en) 2020-10-08
CN102216271B (zh) 2013-09-25
CN102216272B (zh) 2014-02-05
PL2358674T3 (pl) 2013-06-28
US9675599B2 (en) 2017-06-13
AU2009313948A1 (en) 2010-05-20
AR074350A1 (es) 2011-01-12
US20190142816A1 (en) 2019-05-16
US9187423B2 (en) 2015-11-17
US11723900B2 (en) 2023-08-15
BRPI0921595B8 (pt) 2021-05-25
US10034870B2 (en) 2018-07-31
TW201024263A (en) 2010-07-01
US20180050024A1 (en) 2018-02-22
JP2012508759A (ja) 2012-04-12
JP2012508760A (ja) 2012-04-12
KR20110082196A (ko) 2011-07-18
SI2358674T1 (sl) 2013-04-30
RU2011123875A (ru) 2012-12-20
CO6361993A2 (es) 2012-01-20
US20140057944A1 (en) 2014-02-27
HK1160449A1 (en) 2012-08-17
TWI443087B (zh) 2014-07-01
US20180055830A1 (en) 2018-03-01
US20190134019A1 (en) 2019-05-09
US20130030020A1 (en) 2013-01-31
US20160022660A1 (en) 2016-01-28
HRP20120920T1 (hr) 2013-01-31
ZA201103495B (en) 2012-01-25
JP2014098033A (ja) 2014-05-29
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
HRP20130300T1 (hr) 2013-04-30
US20100125092A1 (en) 2010-05-20
US20210290608A1 (en) 2021-09-23
HK1160452A1 (en) 2012-08-17
CO6361988A2 (es) 2012-01-20
EP2358674B1 (en) 2013-01-02
CA2742114A1 (en) 2010-05-20
KR101656338B1 (ko) 2016-09-09
RU2011123890A (ru) 2012-12-20
JP5598798B2 (ja) 2014-10-01
JP2014139209A (ja) 2014-07-31
SI2358675T1 (sl) 2013-01-31
CL2011001093A1 (es) 2011-09-02
EP2358674A1 (en) 2011-08-24
US9162982B2 (en) 2015-10-20
IL212230A (en) 2014-12-31
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20
AU2009313949A1 (en) 2010-05-20
ES2396583T3 (es) 2013-02-22
WO2010056939A1 (en) 2010-05-20
US8247433B2 (en) 2012-08-21
PL2358675T3 (pl) 2013-03-29
PT2358674E (pt) 2013-03-05
JP2014101384A (ja) 2014-06-05
SG171311A1 (en) 2011-07-28
US8304432B2 (en) 2012-11-06
US8304433B2 (en) 2012-11-06
US20230201181A1 (en) 2023-06-29
MX2011005090A (es) 2011-09-06
KR101685186B1 (ko) 2016-12-09
NZ592543A (en) 2013-02-22
EP2358675B9 (en) 2019-09-11
AU2009313951B2 (en) 2015-03-12
US20100125141A1 (en) 2010-05-20
SI2358676T1 (sl) 2013-01-31
SMT201300033B (it) 2013-05-06
BRPI0921593A2 (pt) 2015-08-18
US10226454B2 (en) 2019-03-12
US10441579B2 (en) 2019-10-15
DK2358674T3 (da) 2013-04-08
EP2358676B1 (en) 2012-10-10
AU2009313951A1 (en) 2010-05-20
US10946006B2 (en) 2021-03-16
IL212452A0 (en) 2011-06-30
US8592596B2 (en) 2013-11-26
CA2739992A1 (en) 2010-05-20
JP2012508761A (ja) 2012-04-12
AR114965A2 (es) 2020-11-11
CN102216272A (zh) 2011-10-12
TWI461407B (zh) 2014-11-21
BRPI0921596B1 (pt) 2021-10-26
DK2358676T3 (da) 2013-01-14
PL2358676T3 (pl) 2013-03-29
TW201022206A (en) 2010-06-16
EP2358675A1 (en) 2011-08-24
CN102209712B (zh) 2016-04-06
MX2011005089A (es) 2011-07-29
US20180289687A1 (en) 2018-10-11
AU2009313948B2 (en) 2015-03-12
TW201024264A (en) 2010-07-01
CA2742105A1 (en) 2010-05-20
BRPI0921593B1 (pt) 2021-05-04
KR101656339B1 (ko) 2016-09-09
US20200316047A1 (en) 2020-10-08
RU2503662C2 (ru) 2014-01-10
MY151229A (en) 2014-04-30
US9073859B2 (en) 2015-07-07
KR20110082085A (ko) 2011-07-15
DK2358675T3 (da) 2013-01-14
US20100125093A1 (en) 2010-05-20
WO2010056941A1 (en) 2010-05-20
EP2358676A1 (en) 2011-08-24
CA2739992C (en) 2016-09-20
BRPI0921595B1 (pt) 2020-10-13
CY1113855T1 (el) 2016-07-27
US20140323735A1 (en) 2014-10-30
US10946007B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
CY1113622T1 (el) Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
CY1124622T1 (el) Μεθοδοι θεραπειας του καρκινου με τη χρηση 3-(4-((4-(μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο- 2,6-διονης
CY1118621T1 (el) Πολυμορφικες μορφες του 2-(5-βρωμο-4-(4-κυκλο προπυλναφθαλιν-1-υλ)-4η-1,2,4-τριαζολ-3-υλθειο) οξικου οξεος και χρησεις αυτων
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
CY1121592T1 (el) Μια στερεη μορφη της υδροχλωρικης (s)-3-(4-((4-μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο-2,6-διονης
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1109072T1 (el) Βητα κρυσταλλικη μορφη του υδροχλωρικου αλατος της ιβαμπραδινης, μεθοδος παρασκευης αυτου και φαρμακευτικης συνθεσεις που το περιεχουν
CY1114637T1 (el) 4-[4-({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλο)]καρβαμοϋλ}αμινο)-3-φθοροφαινοξυ]-ν-μεθυλοπυριδινο-2-καρβοξαμιδιο μονοϋδρικο
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
EA201170872A1 (ru) Ингибиторы протеинкиназы
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
EA201270546A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
CY1117962T1 (el) Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης
CY1111275T1 (el) Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου
NO20090250L (no) Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
CY1112366T1 (el) Ενωσεις βενζιμιδαζολης- καρβοξαμιδης ως αγωνιστες του 5-ητ4 υποδοχεα
RS53138B (en) 4- [2- (4-METHYLPHENYLSULPHANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF INJURED INTENTION SYNDROME (IBS).
EA201200868A1 (ru) Ингибиторы диацилглицеролацилтрансферазы
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
NO20076396L (no) Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette
EA201000613A1 (ru) Тризамещенные пиперидины
EA201000611A1 (ru) 4,4-дизамещенные пиперидины